hIgDFc-Ig inhibit B cell functions by regulating BCR-Lyn-Syk-NF-κB signaling pathway in treatment for mice with collagen-induced arthritis

Xian‐Zheng Zhang, Xu Li, Dan Mei, Jinru Ge, Han Wang, Yu Tai, le han, Jinling Shu, Faqin Liang, Xiaoyu Cai, Yue Zhu, Qianqian Yu, feng zhang, Qing Tong Wang, Ling Ling Zhang, Wei WeiAuthorea 2020 · DOI

Abstract

Background and purpose: This study investigates the therapeutic potential of hIgDFc-Ig (DG), a novel biological agent that targets the IgD receptor (IgDR), in treating collagen-induced arthritis (CIA). The research focuses on DG's ability to modulate the B cell antigen-receptor (BCR) signaling pathway. Experimental approach: DBA1 mice were used to model CIA, receiving three doses of DG via intraperitoneal injection. Therapeutic efficacy was evaluated through clinical scoring, histopathology, flow cytometry, and molecular signaling analysis. The mechanism was further explored in vitro using the Daudi human B cell line. Key results: DG treatment significantly improved clinical symptoms and joint pathology in CIA mice. Mechanistically, DG inhibited BCR over-activation by increasing p-Lyn levels and disrupting the Syk-Btk interaction, leading to reduced NF-κB activation and lower immunoglobulin levels. Conclusion: DG acts as a promising immunomodulatory agent for rheumatoid arthritis by specifically regulating the BCR-Lyn-Syk-NF-κB signaling axis.

Introduction

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and progressive bone destruction. B cells are central to RA pathogenesis, contributing through the production of autoantibodies and pro-inflammatory cytokines. While current B cell-depleting therapies like Rituximab are effective, they carry risks of severe immunosuppression. There is a critical need for therapies that can "re-tune" overactive B cells without total depletion. This study evaluates hIgDFc-Ig (DG), a fusion protein designed to competitively bind the IgD receptor (IgDR), as a novel immunomodulatory strategy.

Methods and Mechanism of Action

The researchers employed a combination of in vivo and in vitro models. DBA1 mice with collagen-induced arthritis (CIA) served as the primary disease model, while the Daudi human B cell line was used to dissect molecular pathways. DG works by competing with endogenous IgD for binding to the IgD receptor on the B cell surface. This competitive inhibition was visualized using immunofluorescence to track the spatial relationship between IgDR and the B cell receptor (BCR).

Immunofluorescence staining of Daudi cells showing the localization of IgDR and IgD-BCR, illustrating the target for DG competitive binding.

Key Results

Clinical and Pathological Improvement

DG administration resulted in a significant, dose-dependent reduction in the arthritis index and joint swelling in CIA mice. Histopathological examination confirmed that DG treatment mitigated synovial hyperplasia, inflammatory cell infiltration, and cartilage erosion. Furthermore, DG treatment normalized the proportions of memory B cells and plasma cells in the spleen and peripheral blood.

Functional Inhibition of B Cells

A primary outcome of DG treatment was the suppression of B cell over-activation. Functional assays measuring relative absorbance demonstrated that DG significantly lowered B cell activity compared to untreated CIA controls, with effects comparable to established therapies like Etanercept.

B cell and T cell relative absorbance across treatment groups, demonstrating the dose-dependent inhibitory effect of DG on B cell function.

Molecular Signaling Regulation

The therapeutic effect of DG is mediated through the BCR-Lyn-Syk-NF-κB pathway. DG was found to increase the phosphorylation of Lyn (p-Lyn), a negative regulator of BCR signaling. This "molecular brake" subsequently inhibited the phosphorylation of Syk and Btk and prevented the nuclear translocation of NF-κB (p65). This signaling cascade suppression led to a marked decrease in the production of various immunoglobulins (IgG1, IgG2a, IgE), reducing the autoimmune burden.

Conclusion and Implications

This study demonstrates that hIgDFc-Ig (DG) is an effective therapeutic agent for collagen-induced arthritis. By targeting the IgD receptor and modulating the BCR-Lyn-Syk-NF-κB signaling pathway, DG provides a sophisticated method of controlling B cell-driven inflammation. This approach offers a potential advantage over total B cell depletion by selectively dampening pathogenic activation, making DG a promising candidate for future clinical development in rheumatoid arthritis.

Summary updated

Abstract

Background and purpose: To investigate the effect of hIgDFc-Ig (DG), a new biological agent targets competition for binding to IgD receptors, on collagen-induced arthritis and its potential mechanism in regulating B cell antigen-receptor signaling pathway. Experimental approach: DBA1 mice were used to establish collagen-induced arthritis model, three doses DG were administered by intraperitoneal injection. Clinical assessment of CIA, histopathological examination, flow cytometry, western blotting, immunofluorescence staining, protein chips and so on were used to evaluated therapeutic effects. The competitive effects on BCR-NF-κB signaling pathway were also evaluated in Daudi cell lines in vitro. Key results: We found that DG has a obvious therapeutic effect on CIA mice. DG relieved the clinical assessment of CIA mice and improved the pathology of joints and spleen. In addition, regulated B cell subsets in the PBMC and spleen of CIA mice, and decreased level of immunoglobulins. DG can inhibit the over-activation of BCR signal by increasing p-Lyn level, Co-treatment with DG (0.1-10 μg·ml-1) dose-dependently down-regulated the BCR signaling and decreased the iteraction between Syk and Btk stimulated by IgD in Daudi cell. Conclusion and Implications: DG may play a therapeutic role in CIA mice by regulating BCR-Lyn-Syk-NF-KB signaling pathway, and may be a new promising biological agent for rheumatoid arthritis. Key words: hIgDFc-Ig; B cell antigen receptor; Collagen-induced arthritis; NF-κB signaling pathway
BibTeX
@misc{zhang2020higdfc,
  author = {Xian‐Zheng Zhang and Xu Li and Dan Mei and Jinru Ge and Han Wang and Yu Tai and le han and Jinling Shu and Faqin Liang and Xiaoyu Cai and Yue Zhu and Qianqian Yu and feng zhang and Qing Tong Wang and Ling Ling Zhang and Wei Wei},
  title = {{hIgDFc-Ig inhibit B cell functions by regulating BCR-Lyn-Syk-NF-κB signaling pathway in treatment for mice with collagen-induced arthritis}},
  year = {2020},
  doi = {10.22541/au.158880102.27620598},
  howpublished = {Authorea},
}
Figure